Latest Blogs

Apr 01, 2020
Dr. Mona Hassan arrived in the United States excited for professional development and activism opportunities. Within a week, COVID-19 completely derailed her plans.
Mar 31, 2020
Dr. Inas Abuali attempts to make sense of the shifting tides and what they mean for her patients, colleagues, and loved ones (while maintaining safe social distance from her co-fellows).
Mar 25, 2020
My coauthors and I call on every oncology caregiver and stakeholder to join us in the fight against our lack of information and help us gather the data that will be paramount to guide our practices in this new reality.
Mar 24, 2020
Dr. Anna M. Laucis examines the drivers of professional burnout in oncology, and the devastating cost of failing to acknowledge the effects of burnout.
Subscribe to this column

L. Michael Glode, MD, FACP, FASCO

L. Michael Glodé, MD, FACP, FASCO, is a Professor Emeritus at the University of Colorado Cancer Center. He previously served as Chair of ASCO's Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog to help patients and their families understand various aspects of prostate cancer.

Apr 01, 2020
The TMPRSS2 protein has a role in both COVID-19 and in prostate cancer, suggesting intriguing avenues of inquiry for researchers engaged in the fight against COVID-19.
Sep 09, 2019
A recent study on the risk of Alzheimer's disease or dementia following the use of ADT was disturbing to me on two levels.
Jul 02, 2019
Regardless of prognosis, we all must live with the reality that time is fleeting, and none of us have unlimited tomorrows.
Aug 31, 2018
Some reflections on John McCain, mortality, Hamilton, and the story you leave behind. 
Dec 21, 2016
I cannot count the number of times I have thought to myself, “If it were not for the PSA, you would no doubt be out there playing golf, skiing, biking, taking a grandchild to the park, or just enjoying life.” Living from one PSA to the next is a bad way to mark the passing of time.
Aug 08, 2016
For prostate cancer, there are both challenges and some early positive results from immunotherapy trials that remain intriguing. One of the key challenges is identifying those patients who will benefit from the treatment.

Pages